UA110979C2 - Рідка фармацевтична композиція, яка включає нітизинон - Google Patents

Рідка фармацевтична композиція, яка включає нітизинон

Info

Publication number
UA110979C2
UA110979C2 UAA201400625A UAA201400625A UA110979C2 UA 110979 C2 UA110979 C2 UA 110979C2 UA A201400625 A UAA201400625 A UA A201400625A UA A201400625 A UAA201400625 A UA A201400625A UA 110979 C2 UA110979 C2 UA 110979C2
Authority
UA
Ukraine
Prior art keywords
liquid pharmaceutical
nitisinone
pharmaceutical formulation
nitizinone
fluoromethylbenzoyl
Prior art date
Application number
UAA201400625A
Other languages
English (en)
Inventor
Леннарт СВЕНССОН
Ханс Сіден
Original Assignee
Сведіш Орфан Біовітрум Інтернешнл Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сведіш Орфан Біовітрум Інтернешнл Аб filed Critical Сведіш Орфан Біовітрум Інтернешнл Аб
Publication of UA110979C2 publication Critical patent/UA110979C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Винахід стосується рідкої фармацевтичної композиції, придатної для перорального прийому, яка включає: a) суспензію ефективної кількості мікронізованого 2-(2-нітро-4-грифторметилбензоїл)-1,3-циклогександіону (нітизинону) і b) буфер на основі лимонної кислоти з рН в діапазоні значень від 2,5 до 3,5, переважно рН 3,0.
UAA201400625A 2011-06-23 2012-06-20 Рідка фармацевтична композиція, яка включає нітизинон UA110979C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1150585 2011-06-23
PCT/SE2012/050681 WO2012177214A1 (en) 2011-06-23 2012-06-20 Liquid pharmaceutical composition comprising nitisinone

Publications (1)

Publication Number Publication Date
UA110979C2 true UA110979C2 (uk) 2016-03-10

Family

ID=47422827

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201400625A UA110979C2 (uk) 2011-06-23 2012-06-20 Рідка фармацевтична композиція, яка включає нітизинон

Country Status (22)

Country Link
US (2) US9301932B2 (uk)
EP (1) EP2723320B1 (uk)
JP (1) JP6038132B2 (uk)
CN (1) CN103747781B (uk)
AU (1) AU2012273515B2 (uk)
BR (1) BR112013033008B1 (uk)
CA (1) CA2838039C (uk)
CL (1) CL2013003630A1 (uk)
CY (1) CY1117273T1 (uk)
DK (1) DK2723320T3 (uk)
ES (1) ES2566787T3 (uk)
HR (1) HRP20160286T1 (uk)
HU (1) HUE027304T2 (uk)
IL (1) IL229677A (uk)
MX (1) MX2013014567A (uk)
PL (1) PL2723320T3 (uk)
RS (1) RS54632B1 (uk)
RU (1) RU2605301C2 (uk)
SI (1) SI2723320T1 (uk)
SM (1) SMT201600097B (uk)
UA (1) UA110979C2 (uk)
WO (1) WO2012177214A1 (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723320B1 (en) * 2011-06-23 2016-01-13 Swedish Orphan Biovitrum International AB Liquid pharmaceutical composition comprising nitisinone
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations
EP3137066A1 (en) 2014-04-30 2017-03-08 Swedish Orphan Biovitrum International AB Nitisinone dosing regimens for the treatment of alkaptonuria
CN104623428A (zh) * 2015-03-13 2015-05-20 庄彩梅 一种缓解遗传性酪氨酸血症的中药制剂及其制备方法
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
ITUB20160972A1 (it) * 2016-02-23 2017-08-23 Univ Degli Studi Di Siena Trattamento dell’alkaptonuria e della tirosinemia di tipo 1
CN110464716A (zh) * 2019-09-03 2019-11-19 黄嘉若 一种尼替西农在制备治疗肺癌药物中的用途
CN112107548A (zh) * 2020-10-30 2020-12-22 兆科药业（广州）有限公司 一种含有尼替西农的药物组合物及其制备方法
CN114831974A (zh) * 2022-06-23 2022-08-02 徐州医科大学 尼替西农在制备预防和治疗内毒素性休克疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006158A (en) 1984-12-20 1991-04-09 Ici Americas Inc. Certain 2-(2-substituted benzoyl)-1,3-cyclohexanediones
US4695673A (en) 1985-11-20 1987-09-22 Stauffer Chemical Company Process for the production of acylated 1,3-dicarbonyl compounds
DK0591275T3 (da) * 1991-06-24 1999-10-11 Zeneca Ltd Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyklohexandion til behandling af tyrosinæmi samt farmaceutiske sammen
US5668089A (en) 1996-04-08 1997-09-16 Zeneca Limited Selective corn herbicide
US20050288187A1 (en) 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
GB0405760D0 (en) 2004-03-15 2004-04-21 Syngenta Participations Ag Agrochemical formulation
GB0414895D0 (en) 2004-07-02 2004-08-04 Syngenta Ltd Herbicidal formulation
GB0504103D0 (en) 2005-02-28 2005-04-06 Syngenta Ltd Novel method
JP2010501532A (ja) 2006-08-18 2010-01-21 シンジェンタ リミテッド うつ病、および／または常習性薬物の使用に伴う禁断症状の治療のための、ｈｐｐｄ阻害薬の使用
MX2011004769A (es) * 2008-11-06 2011-11-29 Biotie Therapies Inc Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño.
US8354451B2 (en) * 2009-03-09 2013-01-15 The Uwm Research Foundation, Inc. Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase
EP2723320B1 (en) * 2011-06-23 2016-01-13 Swedish Orphan Biovitrum International AB Liquid pharmaceutical composition comprising nitisinone
WO2013181292A1 (en) 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations

Also Published As

Publication number Publication date
IL229677A0 (en) 2014-01-30
AU2012273515B2 (en) 2016-11-03
IL229677A (en) 2017-03-30
EP2723320B1 (en) 2016-01-13
DK2723320T3 (en) 2016-03-21
RU2605301C2 (ru) 2016-12-20
CN103747781A (zh) 2014-04-23
US9301932B2 (en) 2016-04-05
BR112013033008A2 (pt) 2017-01-31
US20150174081A1 (en) 2015-06-25
JP6038132B2 (ja) 2016-12-07
EP2723320A1 (en) 2014-04-30
JP2014517067A (ja) 2014-07-17
RU2014101990A (ru) 2015-07-27
US20140206771A1 (en) 2014-07-24
CN103747781B (zh) 2018-06-08
CL2013003630A1 (es) 2014-11-21
BR112013033008B1 (pt) 2021-05-18
RS54632B1 (en) 2016-08-31
AU2012273515A1 (en) 2013-12-12
BR112013033008A8 (pt) 2018-03-06
SMT201600097B (it) 2016-04-29
HUE027304T2 (en) 2016-10-28
EP2723320A4 (en) 2014-12-03
CA2838039C (en) 2017-10-24
WO2012177214A1 (en) 2012-12-27
PL2723320T3 (pl) 2016-06-30
ES2566787T3 (es) 2016-04-15
HRP20160286T1 (hr) 2016-05-06
MX2013014567A (es) 2014-08-21
SI2723320T1 (sl) 2016-05-31
NZ618332A (en) 2015-06-26
CY1117273T1 (el) 2017-04-26
CA2838039A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
GB2569249C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents and uses thereof
PH12014502778A1 (en) Antibody formulation
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
BR112015012547A2 (pt) composições de prostaciclina e métodos de sua utilização
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
FR2975004B1 (fr) Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
FR2999934B1 (fr) Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
EA201400444A1 (ru) Производные 2-оксопиперидинила
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина